Evonik Industries has started the planning stage for the construction of an additional world-scale plant complex in Singapore. The facility, which will produce the amino acid DL-methionine for animal nutrition, will have an annual production capacity of 150,000 metric tons and is expected to start operations in 2019.
It still requires authorisation from the Evonik committees. With this decision Evonik follows the global megatrends of health and nutrition, which are driving the growth of the DL-methionine business. With the timely and demand driven expansion of capacities over the past few years Evonik has continuously accompanied this strong market growth. "We are convinced that the market for DL-methionine will continue to show dynamic growth, and we want to contribute to meeting the global demand for this product, which is indispensable for efficient and sustainable animal nutrition worldwide," says Klaus Engel, the Chairman of the Evonik Executive Board.
The construction of the plant complex is planned next to the existing Evonik methionine plant on Jurong Island in Singapore. The location in Singapore allows Evonik to serve especially Asian growth markets well. The specialty chemicals company produces DL-methionine at world-scale plants in Antwerp (Belgium), Wesseling/Cologne (Germany), Mobile (Alabama, USA), and Singapore.
Evonik sells DL-methionine under the brand name MetAMINO®.
To comment, login here
Or register to be able to comment.